Pharmaceutical Technology on MSN7d
Gilead’s lenacapavir applications for HIV gain EMA validationGilead Sciences has announced EMA validation for a parallel accelerated review of lenacapavir’s MAA and EU-M4all applications ...
The FDA has accepted under Priority Review the NDA for lenacapavir for the prevention of HIV as pre-exposure prophylaxis.
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...
Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...
Gilead Sciences has allocated USD 200 million to potentially settle with federal prosecutors to resolve an investigation into ...
A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...
Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...
GlobalData on MSN13d
Gilead’s lenacapavir moves closer to FDA approval for HIV PrEP useLenacapavir is already approved under the name Sunlenca as an HIV treatment for patients resistant to other medication ...
A revolutionary advancement in HIV prevention technology stands at a critical crossroads as recent policy decisions threaten ...
The study, published Jan. 30 in the Journal of Antimicrobial Chemotherapy, adds to growing evidence that lenacapavir may be a powerful new tool in the global anti-HIV drug arsenal.Approximately, 1 ...
US antivirals giant Gilead Sciences recently announced that the US Food and Drug Administration (FDA) has accepted its New ...
A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback